Development of an affinity silica monolith containing human serum albumin for chiral separations.
An affinity monolith based on silica and containing immobilized human serum albumin (HSA) was developed and evaluated in terms of its binding, efficiency and selectivity in chiral separations. The results were compared with data obtained for the same protein when used as a chiral stationary phase with HPLC-grade silica particles or a monolith based on a copolymer of glycidyl methacrylate (GMA) and ethylene dimethacrylate (EDMA). The surface coverage of HSA in the silica monolith was similar to values obtained with silica particles and a GMA/EDMA monolith. However, the higher surface area of the silica monolith gave a material that contained 1.3-2.2-times more immobilized HSA per unit volume when compared to silica particles or a GMA/EDMA monolith. The retention, efficiency and resolving power of the HSA silica monolith were evaluated using two chiral analytes: d/l-tryptophan and R/S-warfarin. The separation of R- and S-ibuprofen was also considered. The HSA silica monolith gave higher retention and higher or comparable resolution and efficiency when compared with HSA columns that contained silica particles or a GMA/EDMA monolith. The silica monolith also gave lower back pressures and separation impedances than these other materials. It was concluded that silica monoliths can be valuable alternatives to silica particles or GMA/EDMA monoliths when used with immobilized HSA as a chiral stationary phase.
Mallik
Rangan
R
Chemistry Department, University of Nebraska, Lincoln, NE 68588-0304, USA.
Hage
David S
DS
D002846:Chromatography, Affinity; D006801:Humans; D007052:Ibuprofen / Q000737:chemistry / Q000302:isolation & purification*; D008768:Methylmethacrylates / Q000737:chemistry; D008956:Models, Chemical; D010316:Particle Size; D010539:Permeability; D011312:Pressure; D015203:Reproducibility of Results; D012545:Schiff Bases / Q000737:chemistry; D012709:Serum Albumin / Q000737:chemistry*; D012822:Silicon Dioxide / Q000737:chemistry*; D013237:Stereoisomerism; D013499:Surface Properties; D013678:Technology, Pharmaceutical / Q000379:methods*; D014364:Tryptophan / Q000737:chemistry / Q000302:isolation & purification*; D014859:Warfarin / Q000737:chemistry / Q000302:isolation & purification*
D008768:Methylmethacrylates; D012545:Schiff Bases; D012709:Serum Albumin; C020347:GMA-EDMA; D014859:Warfarin; D012822:Silicon Dioxide; D014364:Tryptophan; D007052:Ibuprofen